RayzeBio, Inc. Common Stock
RYZB · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.10 | -0.10 | 0.00 |
| FCF Yield | -6.46% | -3.80% | -0.29% |
| EV / EBITDA | -11.65 | -23.79 | -122.91 |
| Quality | |||
| ROIC | -22.86% | -18.57% | -4.69% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.75 | 1.06 | 0.34 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -65.51% | -1,214.82% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 1.68 | 1.07 | 21.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |